ALVIO — Valerio Therapeutics SA Share News
0.000.00%
Last trade - 00:00- €195.03m
- €201.58m
- €2.57m
Brief: Onxeo announces another positive DSMB recommendation for Livatag
Brief: Onxeo announces promising results from preclinical study of Beleodaq
Brief: Onxeo SA Q3 revenues up at 1.23 mln euros
Brief: Onxeo issues 5,434,783 new shares for 12.5 million euros
Brief: Onxeo announces first outcomes of Livatag preclinical plan
Brief: Onxeo S.A. says combination of AsiDNA and PARP inhibitors demonstrates synergistic effect
Corrected: BRIEF-Onxeo H1 net loss narrows to 11.2 million euros (July 28)
Corrected: BRIEF-Onxeo H1 net loss narrows to 11.2 million euros (July 28)
Brief: Onxeo Livatag H1 net loss narrows to 11.2 million euros
Brief: Onxeo signs exclusive license agreement with Pint Pharma
Brief: Onxeo gets USPTO notice of allowance for AsiDNATM Patent
Brief: Onxeo announces development of Beleodaq Oral formulation
Brief: Onxeo says cash position sufficient to fund development into H2 2017
Brief: Onxeo Q1 revenue down at 782,000 euro
Brief: Onxeo reports positive data for Livatag
Brief: Onxeo closes DNA Therapeutics acquisition
Brief: Onxeo establishes US subsidiary
Brief: Onxeo acquires DNA Therapeutics
Brief: Onxeo FY consolidated net loss widens to 19.4 million euros